ANDA 63142, held by Hq Speclt Pharma. Ampicillin Sodium.
As of Nov 16, 2026, ANDA 63142 (Ampicillin Sodium), held by Hq Speclt Pharma, was first approved by FDA on Apr 15, 1993, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 1993 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ampicillin SodiumEQ 10GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| May 1, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| Feb 21, 2018 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 21, 2018 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 12, 2017 | Supplement 12Manufacturing | Approved | None posted |
| Jun 28, 2013 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jul 23, 2007 | Supplement 6Labeling | Approved | None posted |
| Feb 28, 2007 | Supplement 4Labeling | Approved | None posted |
| Feb 14, 1994 | Supplement 1Manufacturing | Approved | None posted |
| Nov 5, 1993 | Supplement 2Manufacturing | Approved | None posted |
| Apr 15, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters